Participated · Series A · Jul 2020

Artiria Medical builds a real-time deflectable guidewire technology intended for neurointerventional procedures to improve minimally invasive treatment of stroke. The company reports promising first-in-human results and has obtained FDA clearance. Its technology is already showing traction among neurointerventional physicians. Artiria secured financing to enable further clinical deployment and to complete its clinical studies. The recent financing mix underscores investor support as the company advances clinical work. Artiria Medical, an EPFL spin-off, has developed a neurovascular guiding system designed to navigate tiny brain arteries and speed delivery of life‑saving stroke therapies. The company says its technology integrates well into current clinical practice and addresses delays caused by challenging device navigation. With the new funding, Artiria plans to significantly advance the clinical and regulatory deployment of its first product. The announcement notes the company won Venture Kick and participated in Venture Leaders Life Science, which helped prepare fundraising and investor outreach. No revenue or user metrics were disclosed in the article. The financing is intended to accelerate clinical development and regulatory progress toward patient use. ARTIRIA Medical, an EPFL spin-off founded in August 2019 by Guillaume Petit‑Pierre and Marc Boers, has developed a patented micro‑actuated guidewire that facilitates micromotion deep in brain arteries to enable seamless navigation to cerebral lesions. The device aims to ease minimally invasive stroke procedures, reduce treatment duration, and improve patient outcomes against the backdrop of some 13 million annual strokes. The company plans to use its new funding to accelerate clinical validation and pursue regulatory approval of its first product. Less than one year after its foundation the start‑up closed a CHF 3 million financing to support those next stages. Leadership includes the two founders, and the company recently appointed Jacques Essinger, Jean‑Pierre Rosat, and Didier Cowling to its board to add medical device expertise.

Participated · Seed · Dec 2019

Nagi Bioscience develops next-generation laboratory equipment intended to unlock the potential of alternatives to animal testing and to disrupt drug discovery and toxicology testing. Its first commercial product, SydLab One, launched at the end of Q1 2023 and has gained traction in biopharma and agrochemical R&D. The company emphasizes close customer collaboration and co-creation to validate product-market fit and guide future development. Nagi plans to use new funding to scale its commercial organization and operations while expanding R&D to strengthen its portfolio of products. Management says the company aims to open new markets and form partnerships across industries such as cosmetics, food, agro and pharma. The business is based in Switzerland and positions its technology as a more humane, faster and cost-effective alternative to many mammalian tests. Nagi Bioscience develops an “Organism-on-Chip” technology that combines microfluidics with the microscopic worm C. elegans to provide an alternative to traditional animal testing. The platform targets pharmaceutical, chemical, cosmetic industries and biomedical research and aligns with the 3Rs principles (replacement, reduction, refinement). The company has prototypes under validation in collaboration with industrial partners in the chemical and biotech fields. Nagi intends to use the financing to complete development of its first product and prepare market access. Financially, the company closed a CHF1.8m seed financing round. Nagi was founded in January 2019 by Dr. Matteo Cornaglia (CEO) and Dr. Laurent Mouchiroud (CSO) as a spin-off from EPFL and is based in Lausanne. The board recently added Dr. Chris Radloff, who brings 20+ years of life-science-tech experience and angel investing experience.

Participated · Series B · Apr 2018

Arviem installs automated locating and sensing technology on multimodal containers and cargo to collect data and uncover supply-chain blind spots. It offers cargo monitoring as a fully managed service, including monitoring devices, a data analytics platform, and device logistics and maintenance. The company delivers real-time, carrier-independent location and condition data across the full journey from manufacture to delivery, giving actionable insights to develop cost-saving strategies, assess performance, and identify bottlenecks. After closing a multimillion financing agreement with Swiss financial company Kineo Finance, Arviem reported more than 40% revenue growth in Q3 2022 versus Q1 and Q2 and increased service capacity by over 40% during the year. The company submitted nearly 40% more proposals in 3Q 2022 compared with 2Q 2022 and saw an increase in the average total contract value of proposals. Arviem has launched a new Asian business unit with sales and operations employees in Singapore to serve that market and expects the expansion to contribute to growth in 2023 and beyond. Arviem provides IoT-enabled cargo monitoring devices that transmit real-time location and condition data to a cloud-based supply-chain analytics platform. Its service connects intermodal containers, cargo, vessels and trailers to eliminate logistics blind spots and supports global deployments across various industries. The company uses a pay-per-use pricing model to let corporate clients adopt the service without upfront hardware, software or staffing investments. After ten years of operations, Arviem has driven rapid customer adoption and amassed a large dataset it plans to leverage. The new funding will be used to expand the service portfolio, including development of supply chain financing and supply chain risk-profiling offerings to create a one-stop supply-chain service ecosystem. Arviem is led by founder and CEO Stefan Reidy and is Swiss-based, with total funding now at US$15 million following the Series B close. Arviem offers real-time end-to-end cargo monitoring and analytics that deliver accurate shipment data to help clients optimize supply chains and reduce costs. Its service is used by blue-chip customers including DOW Chemical, Nestlé, Bacardi and Hellmann Worldwide Logistics. The company recently completed a CHF 1.35 million financing round and says the proceeds will allow it to reach profitability this year. Arviem plans to invest the funds in its core value proposition—data analytics—and to enhance front office processes to enable accelerated growth. The product emphasizes providing actionable, real-time data so customers can make critical decisions and lower logistics costs. The company is based in Zug and focuses on supplying enterprise-grade supply-chain visibility solutions.

Participated · Series B · Dec 2017

ActLight is an EPFL-based startup that develops and licenses light sensor technology for applications such as range meters and 3D cameras. Its sensors deliver comparable performance while using up to ten times less energy, occupying less space and offering better pricing than existing solutions. The company has developed a low-energy heart-rate sensing sensor for wearable devices in cooperation with US firm On Semiconductor. That sensor can measure a heartbeat using merely one-fifth of the energy required by existing solutions; the article notes that nearly 80% of smartwatch battery power is consumed by heart-rate monitoring. ActLight licenses its technology to device makers and targets energy-efficient sensing applications. The company recently closed a Series B with participation from strategic investors and business angels.

Participated · Series A · May 2017

DBS System develops and sells microfluidic blood collection devices under its patented HemaXis™ platform. The company is producing and selling its first-generation HemaXis DB for whole blood collection and is establishing partnerships with major labs in Europe and the US. It is industrializing a second-generation HemaXis device that passively separates plasma or serum from whole blood, expanding the range of tests that can be run on dried blood spot samples by certified laboratories. DBS System plans to use the new funding to industrialize that second-generation device and scale manufacturing. The company is led by CEO Eric Ödman and positions itself as a manufacturer of devices for collecting and preparing micro samples of whole blood, plasma and serum. It is based in Gland, Switzerland and recently closed a new funding round to support product industrialization.